The gene therapy business development space has been active, and Pfizer Inc. is the latest to announce a deal in the research area with an option to buy the privately-held French gene therapy developer Vivet Therapeuticss. The companies announced March 20 that Pfizer has acquired a 15% equity stake in Vivet and secured an exclusive license to acquire outstanding shares in exchange for €45m ($51m) up front.
The deal will further expand Pfizer's footprint in gene therapy, where it has been building a significant presence, with several...








